Strategic Partnerships:
Long‑running collaborations with Boehringer Ingelheim and Otsuka, plus a 2025 strategic investment from Dassault Systèmes/Medidata, reinforce scale and credibility. Evidence suggests these alliances provide development resources, commercialization pathways, and platform reach.
Product Line Growth:
Multiple FDA authorizations (Rejoyn for MDD; CT‑132 for preventive episodic migraine) and the acquisition of AspyreRx expand the portfolio across psychiatry, neurology, and cardiometabolic care. Late‑stage CT‑155 Phase 3 success and Breakthrough Device status add pipeline depth.
Investor Backing & Capital Strength:
Recent fundraising and M&A momentum amid a consolidating market indicate access to capital and financial resilience. This capital base supports evidence generation, scaling, and entry into new categories.
